- Home
- TOYO vs RGLS Comparison
TOYO vs RGLS Comparison
Compare TOYO & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOYO
- RGLS
- Stock Information
- Founded
- TOYO 2022
- RGLS 2007
- Country
- TOYO Japan
- RGLS United States
- Employees
- TOYO N/A
- RGLS N/A
- Industry
- TOYO
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- TOYO
- RGLS Health Care
- Exchange
- TOYO NYSE
- RGLS Nasdaq
- Market Cap
- TOYO 115.2M
- RGLS 102.1M
- IPO Year
- TOYO N/A
- RGLS 2012
- Fundamental
- Price
- TOYO $3.62
- RGLS $1.60
- Analyst Decision
- TOYO
- RGLS Strong Buy
- Analyst Count
- TOYO 0
- RGLS 6
- Target Price
- TOYO N/A
- RGLS $10.33
- AVG Volume (30 Days)
- TOYO 2.6M
- RGLS 261.9K
- Earning Date
- TOYO 08-21-2024
- RGLS 11-07-2024
- Dividend Yield
- TOYO N/A
- RGLS N/A
- EPS Growth
- TOYO N/A
- RGLS N/A
- EPS
- TOYO 0.76
- RGLS N/A
- Revenue
- TOYO $200,455,385.00
- RGLS N/A
- Revenue This Year
- TOYO N/A
- RGLS N/A
- Revenue Next Year
- TOYO N/A
- RGLS N/A
- P/E Ratio
- TOYO $4.58
- RGLS N/A
- Revenue Growth
- TOYO N/A
- RGLS N/A
- 52 Week Low
- TOYO $1.36
- RGLS $1.08
- 52 Week High
- TOYO $15.61
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- TOYO N/A
- RGLS 52.02
- Support Level
- TOYO N/A
- RGLS $1.53
- Resistance Level
- TOYO N/A
- RGLS $1.70
- Average True Range (ATR)
- TOYO 0.00
- RGLS 0.10
- MACD
- TOYO 0.00
- RGLS 0.00
- Stochastic Oscillator
- TOYO 0.00
- RGLS 35.19
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries is engaged in research and development, production, and sales of solar cells.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.